Sugi Predict

Sugi Predict / Compounds / SCHEMBL19732801

SCHEMBL19732801

SCHEMBL19732801

Nc1ncnc2c1c(I)nn2C1CCC(F)(F)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 7/20 0.68
▸ KDR P35968 7/20 0.68
▸ RET P07949 2/20 0.68
▸ JAK2 O60674 2/20 0.68
▸ DYRK3 O43781 2/20 0.68
▸ CDK1 P06493 2/20 0.68
▸ ROS1 P08922 2/20 0.68
▸ RPS6KB1 P23443 2/20 0.68
▸ CDK2 P24941 2/20 0.68
▸ CSNK1A1 P48729 2/20 0.68
▸ CSNK1D P48730 2/20 0.68
▸ CLK2 P49760 2/20 0.68
▸ IRAK1 P51617 2/20 0.68
▸ CDK5 Q00535 2/20 0.68
▸ DYRK1A Q13627 2/20 0.68
▸ NTRK3 Q16288 2/20 0.68
▸ SLK Q9H2G2 2/20 0.68
▸ CLK4 Q9HAZ1 2/20 0.68
▸ CDC7 O00311 1/20 0.68
▸ PLK4 O00444 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24096480 0.87 JAK2 (0.86) SRCKDRRETJAK2DYRK3
SCHEMBL19732645 0.87 SRC (0.68) SRCKDRRETJAK2DYRK3
SCHEMBL24096505 0.86 SRC (0.64) SRCKDRRETJAK2DYRK3
SCHEMBL401336 0.85 KDR (0.77) SRCKDRRETJAK2DYRK3
SCHEMBL1318717 0.85 SRC (0.77) SRCKDRRETJAK2DYRK3
SCHEMBL19304165 0.84 SRC (0.48) SRCKDRRETJAK2DYRK3
SCHEMBL5805110 0.84 RET (0.64) SRCKDRRETJAK2DYRK3
SCHEMBL23847456 0.83 KDR (0.75) SRCKDRRETJAK2DYRK3
SCHEMBL4826075 0.82 KDR (0.78) SRCKDRRETJAK2DYRK3
SCHEMBL17911543 0.82 KDR (0.78) SRCKDRRETJAK2DYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108697714-B Fused pyrimidine compound or salt thereof 大鹏药品工业株式会社 2022-04-26 — — CN disclosed
US-11236096-B2 Fused pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2022-02-01 — — US disclosed
US-11046696-B2 Fused pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-06-29 — — US disclosed
US-11046696-B2 Fused pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-06-29 — — US disclosed
EP-3260454-B1 CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2021-06-09 — — EP disclosed
US-11014930-B2 Fused pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-05-25 — — US disclosed
US-11008324-B2 — — 2021-05-18 — — US disclosed
US-11008324-B2 — — 2021-05-18 — — US disclosed
US-10981920-B2 — — 2021-04-20 — — US disclosed
US-10807986-B2 Fused pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-10-20 — — US disclosed
US-20190092776-A1 FUSED PYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2019-03-28 — — US disclosed
US-10233189-B2 Fused pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2019-03-19 — — US disclosed
US-10179788-B2 — — 2019-01-15 — — US disclosed
US-10155768-B2 Fused pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-12-18 — — US disclosed
EP-3269370-A1 NOVEL CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2018-01-17 — — EP disclosed
EP-3269370-A1 NOVEL CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2018-01-17 — — EP disclosed
US-20180009818-A1 NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-01-11 — — US disclosed
US-20180009817-A1 FUSED PYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-01-11 — — US disclosed
US-20180009818-A1 NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-01-11 — — US disclosed
EP-3260454-A1 CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2017-12-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236096-B2 Fused pyrimidine compound or salt thereof RET, RB1, MECP2 SRC 153/4885KDR 847/4885RET 1/4885
US-20180009818-A1 NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF RET, ZFX, PDCD11 SRC 456/4885KDR 938/4885RET 1/4885
US-11046696-B2 Fused pyrimidine compound or salt thereof RET, ZFX, MECP2 SRC 259/4885KDR 842/4885RET 1/4885
US-11008324-B2 — RET, GFRA1, GFRA2 SRC 235/4885KDR 605/4885RET 1/4885
US-10179788-B2 — RET, GFRA1, GFRA2 SRC 146/4885KDR 709/4885RET 1/4885
US-10233189-B2 Fused pyrimidine compound or salt thereof RET, RB1, MECP2 SRC 153/4885KDR 847/4885RET 1/4885
US-20180009817-A1 FUSED PYRIMIDINE COMPOUND OR SALT THEREOF RET, RB1, MECP2 SRC 153/4885KDR 847/4885RET 1/4885
US-11014930-B2 Fused pyrimidine compound or salt thereof RET, RB1, MECP2 SRC 153/4885KDR 847/4885RET 1/4885
US-10155768-B2 Fused pyrimidine compound or salt thereof RET, ZFX, MECP2 SRC 259/4885KDR 842/4885RET 1/4885
US-10807986-B2 Fused pyrimidine compound or salt thereof RET, ZFX, MECP2 SRC 259/4885KDR 842/4885RET 1/4885
US-10981920-B2 — RET, GFRA1, GFRA2 SRC 146/4885KDR 709/4885RET 1/4885
US-20190092776-A1 FUSED PYRIMIDINE COMPOUND OR SALT THEREOF RET, RB1, MECP2 SRC 153/4885KDR 847/4885RET 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.